検索結果

Management Policy | About Senju | SENJU Pharmaceutical

ecessary and valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased ...

re safer and more reliable use. For this approval, a bioequivalence study was conducted on patients with primary open-angle glaucoma or ocular hypertension, confirming that the new formulation has the...

ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...

ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...

Mytear EYETECT | OTC Products, etc. | Products | SENJU Pharmaceutical

r something Persons who have suffered from the following symptom: Severe eye pain Persons diagnosed with the following condition: Glaucoma 2. Stop using this medicine immediately and consult a physici...